bimekizumab
Jump to navigation
Jump to search
Indications
- investigational drug for treatment of moderate-to-severe plaque psoriasis[1]
- investigational drug for treatment of hidradenitis suppurativa[2]
Mechanism of action
- humanized lgG1 monoclonal antibody
- inhibits IL-17, IL17A & IL17F
More general terms
References
- ↑ 1.0 1.1 Bassett M Psoriasis Falls to Novel Biologic Bimekizumab brings clear or almost clear skin to vast majority of patients in phase II trial. MedPage Today. February 19, 2018 https://www.medpagetoday.com/meetingcoverage/aad/71243
Papp K, et al Dual neutralization of interleukin (IL)-17A and IL-17F with bimekizumab in moderate-to-severe psoriasis: Results from a phase 2b, randomized, double-blinded, placebo-controlled, dose-ranging study. American Academy of Dermatology (AAD) 2018 - ↑ 2.0 2.1 Bosworth T Studies Validate IL-17 as Hidradenitis Suppurativa Drug Target. Medscape. March 20, 2023 https://www.medscape.com/viewarticle/989861